Loading...

Biocept

DB:B002
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
B002
DB
$18M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Biocept has significant price volatility in the past 3 months.
B002 Share Price and Events
7 Day Returns
-3%
DB:B002
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:B002
-10.2%
DE Biotechs
-6%
DE Market
B002 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biocept (B002) -3% -4.5% -48.5% - - -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on B002.
  • No trading data on B002.
Price Volatility
B002
Industry
5yr Volatility vs Market

B002 Value

 Is Biocept undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Biocept. This is due to cash flow or dividend data being unavailable. The share price is €0.876.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biocept's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biocept's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:B002 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-9.01
NasdaqCM:BIOC Share Price ** NasdaqCM (2019-04-18) in USD $0.98
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biocept.

DB:B002 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BIOC Share Price ÷ EPS (both in USD)

= 0.98 ÷ -9.01

-0.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocept is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Biocept is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Biocept's expected growth come at a high price?
Raw Data
DB:B002 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.11x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
16.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biocept, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biocept's assets?
Raw Data
DB:B002 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.66
NasdaqCM:BIOC Share Price * NasdaqCM (2019-04-18) in USD $0.98
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:B002 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BIOC Share Price ÷ Book Value per Share (both in USD)

= 0.98 ÷ 0.66

1.49x

* Primary Listing of Biocept.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocept is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Biocept's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biocept has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

B002 Future Performance

 How is Biocept expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biocept expected to grow at an attractive rate?
  • Unable to compare Biocept's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Biocept's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Biocept's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:B002 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:B002 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 16.7%
DB:B002 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 50.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:B002 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:B002 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 92 -5 1
2022-12-31 56 -19 1
2021-12-31 32 -22 1
2020-12-31 16 -22 1
2019-12-31 7 -23 1
DB:B002 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -22 -25
2018-09-30 3 -23 -25
2018-06-30 4 -22 -24
2018-03-31 4 -21 -24
2017-12-31 5 -20 -22
2017-09-30 5 -18 -20
2017-06-30 5 -16 -19
2017-03-31 5 -15 -18
2016-12-31 3 -16 -18
2016-09-30 2 -16 -19
2016-06-30 1 -16 -19
2016-03-31 1 -16 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biocept is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Biocept's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:B002 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Biocept Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B002 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.12 -0.12 -0.12 1.00
2022-12-31 -0.45 -0.45 -0.45 1.00
2021-12-31 -0.56 -0.56 -0.56 1.00
2020-12-31 -0.68 -0.68 -0.68 1.00
2019-12-31 -1.24 -1.24 -1.24 1.00
DB:B002 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -9.01
2018-09-30 -12.40
2018-06-30 -15.44
2018-03-31 -19.47
2017-12-31 -23.58
2017-09-30 -25.95
2017-06-30 -31.62
2017-03-31 -40.88
2016-12-31 -57.63
2016-09-30 -78.01
2016-06-30 -83.05
2016-03-31 -85.96

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biocept will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Biocept's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biocept has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

B002 Past Performance

  How has Biocept performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biocept's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biocept does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Biocept's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biocept's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biocept's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biocept Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B002 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.25 -25.21 12.99 4.47
2018-09-30 3.39 -24.86 13.21 4.09
2018-06-30 3.74 -24.00 13.52 3.86
2018-03-31 4.19 -23.54 13.92 3.68
2017-12-31 5.07 -21.61 13.53 3.36
2017-09-30 5.37 -20.13 13.06 3.12
2017-06-30 5.30 -19.06 12.74 2.87
2017-03-31 4.68 -17.96 12.01 2.74
2016-12-31 3.22 -18.40 11.61 2.71
2016-09-30 2.15 -18.83 11.47 2.83
2016-06-30 1.27 -18.58 10.96 2.91
2016-03-31 0.68 -18.02 10.36 2.93
2015-12-31 0.61 -16.95 9.57 2.86
2015-09-30 0.47 -16.21 9.02 3.14
2015-06-30 0.31 -15.58 8.21 3.78
2015-03-31 0.26 -14.54 7.45 4.14
2014-12-31 0.13 -15.87 7.34 4.50
2014-09-30 0.08 -14.46 6.01 4.14
2014-06-30 0.10 -13.46 4.95 3.80
2014-03-31 0.13 -12.44 4.00 3.39
2013-12-31 0.13 -9.23 2.66 3.09
2013-09-30 0.14 -9.71 2.50 3.63
2013-06-30 0.13 -9.72 2.34 4.17
2013-03-31 0.11 -10.96 2.61 5.37
2012-12-31 0.11 -12.26 2.85 6.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biocept has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biocept has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biocept improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biocept's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biocept has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

B002 Health

 How is Biocept's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biocept's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biocept is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biocept's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biocept's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biocept Company Filings, last reported 3 months ago.

DB:B002 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 3.04 1.63 3.42
2018-09-30 8.94 1.71 8.96
2018-06-30 2.53 2.06 2.57
2018-03-31 8.51 2.35 9.27
2017-12-31 1.30 2.79 2.15
2017-09-30 4.03 3.02 5.88
2017-06-30 7.34 3.51 10.00
2017-03-31 10.42 3.79 14.04
2016-12-31 0.66 4.17 4.61
2016-09-30 -4.56 4.37 0.68
2016-06-30 -0.42 4.33 3.75
2016-03-31 -0.49 4.61 4.57
2015-12-31 3.69 4.67 8.82
2015-09-30 6.93 4.95 12.54
2015-06-30 11.05 5.16 16.52
2015-03-31 13.58 4.89 19.29
2014-12-31 -0.22 4.89 5.36
2014-09-30 3.34 4.87 8.82
2014-06-30 6.88 4.71 12.46
2014-03-31 9.36 0.02 10.42
2013-12-31 -12.46 7.40 0.07
2013-09-30 -3.51 1.55 0.30
2013-06-30 -8.22 3.91 0.00
2013-03-31 -27.38 22.63 0.19
2012-12-31 -27.38 22.63 0.19
  • Biocept's level of debt (53.5%) compared to net worth is high (greater than 40%).
  • Biocept had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Biocept has less than a year of cash runway based on current free cash flow.
  • Biocept has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.1% each year.
X
Financial health checks
We assess Biocept's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biocept has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

B002 Dividends

 What is Biocept's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biocept dividends.
If you bought €2,000 of Biocept shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biocept's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biocept's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:B002 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:B002 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biocept has not reported any payouts.
  • Unable to verify if Biocept's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biocept's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biocept has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biocept's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biocept afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biocept has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

B002 Management

 What is the CEO of Biocept's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Nall
COMPENSATION $439,720
AGE 55
TENURE AS CEO 5.7 years
CEO Bio

Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales, marketing, operations and reimbursement. Before joining Biocept, Mr. Nall served at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 to August 2013, with his last position being General Manager, North American Sales and Marketing. He served as Account Executive at Impath. Prior to joining Biocept, He served as General Manager for Clarient, a GE Healthcare Company, responsible for all commercial operations including Sales, Marketing, Client Services and Reimbursement. He joined Clarient in 2002 when it was a small publicly traded company and served in several leadership roles including Director, Vice President of Sales, Vice President of Sales and Reimbursement and finally GM. During the time, he was with Clarient, company grew to over $110 million in revenue and was acquired by GE Healthcare. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010. Prior to joining Clarient, He was with Impath, an innovative cancer diagnostic company. He has been a Director at Biocept, Inc. since 2013. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (also known as the University of Central Missouri).

CEO Compensation
  • Mike's compensation has been consistent with company performance over the past year.
  • Mike's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Biocept management team in years:

2.8
Average Tenure
60
Average Age
  • The tenure for the Biocept management team is about average.
Management Team

Mike Nall

TITLE
CEO, President & Director
COMPENSATION
$440K
AGE
55
TENURE
5.7 yrs

Tim Kennedy

TITLE
CFO, Senior VP of Operations & Corporate Secretary
COMPENSATION
$359K
AGE
60
TENURE
2.8 yrs

Lyle Arnold

TITLE
Senior VP of R&D
COMPENSATION
$287K
AGE
71
TENURE
7.9 yrs

Soon Kap Hahn

TITLE
TENURE
22.3 yrs

Pavel Tsinberg

TITLE
Director of Technology Development
TENURE
1.6 yrs

Michael Brown

TITLE
General Counsel and Compliance & Privacy Officer
TENURE
1.5 yrs

David Moskowitz

TITLE
Vice President of Strategy & Corporate Communications
TENURE
2.5 yrs

Mike Terry

TITLE
Senior Vice President of Corporate Development
AGE
63

Cory Dunn

TITLE
Vice President of Marketing
TENURE
0.4 yrs

Veena Singh

TITLE
Senior Medical Director
COMPENSATION
$442K
AGE
43
TENURE
4.3 yrs
Board of Directors Tenure

Average tenure and age of the Biocept board of directors in years:

8
Average Tenure
70
Average Age
  • The tenure for the Biocept board of directors is about average.
Board of Directors

David Hale

TITLE
Non-Executive Chairman of the Board
COMPENSATION
$102K
AGE
69
TENURE
8.1 yrs

Mike Nall

TITLE
CEO, President & Director
COMPENSATION
$440K
AGE
55
TENURE
6.3 yrs

Claire Reiss

TITLE
Chairwoman Emeritus
TENURE
8 yrs

Lyle Arnold

TITLE
Senior VP of R&D
COMPENSATION
$287K
AGE
71

M. Wilson

TITLE
Lead Independent Director
COMPENSATION
$56K
AGE
80

Ivor Royston

TITLE
Independent Director
COMPENSATION
$41K
AGE
72
TENURE
9.3 yrs

Marsha Chandler

TITLE
Independent Director
COMPENSATION
$40K
AGE
73
TENURE
5.4 yrs

Bruce Huebner

TITLE
Director
COMPENSATION
$48K
AGE
67
TENURE
5.4 yrs

Bruce Gerhardt

TITLE
Independent Director
COMPENSATION
$39K
AGE
67
TENURE
8.5 yrs

Fred Hirsch

TITLE
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Oct 18 Sell Ally Bridge Group Company 05. Oct 18 08. Oct 18 -56,033 €2.25 €-121,089
X
Management checks
We assess Biocept's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biocept has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

B002 News

Simply Wall St News

B002 Company Info

Description

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company’s cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Details
Name: Biocept, Inc.
B002
Exchange: DB
Founded: 1997
$16,422,919
18,867,464
Website: http://www.biocept.com
Address: Biocept, Inc.
5810 Nancy Ridge Drive,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BIOC Common Stock Nasdaq Capital Market US USD 05. Feb 2014
DB B002 Common Stock Deutsche Boerse AG DE EUR 05. Feb 2014
BST B001 Common Stock Boerse-Stuttgart DE EUR 05. Feb 2014
Number of employees
Current staff
Staff numbers
89
Biocept employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:52
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.